Neovacs Finishes Enrolling Patients in Trial Testing Potential SLE Vaccine

French pharmaceutical firm Neovacs has completed enrollment for a Phase 2b clinical trial (IFN-K-002) to evaluate the efficacy and safety of IFNα-Kinoid to treat systemic lupus erythematosus (SLE). “The completion of enrollment is an important milestone for our IFN Kinoid program and confirms the interest of leading clinicians conducting our trial in this novel…

Neovacs to Give Update on Potential Lupus Vaccine, Now in Phase 2 Trial, at Conference

Neovacs will present an update on the company’s interferon alpha (IFNα) Kinoid vaccine program for lupus, dermatomyositis and type 1 diabetes at the upcoming 2017 Keystone Symposia Conference taking place in Banff, Alberta, Canada. Géraldine Grouard-Vogel, PhD, the company’s chief scientific officer, is set to give the  presentation — “Overexpression of IFNalpha…

NEOVACS’ Investigational New Drug Application for Lupus Approved by South Korean Health Authority

French company NEOVACS announced that its Investigational New Drug (IND) application for IFNα Kinoid in lupus, now in Phase 2b development, was approved by the South Korean Health Authority. NEOVACS was established in 1993. Today, the biotech is a leader in active immunotherapy technology platforms (Kinoids) for autoimmune and/or inflammatory diseases. NEOVACS…

Neovacs and Stellar Biotechnologies Partner Up to Form Neostell SAS

Neovacs and Stellar Biotechnologies have collaborated to form a new biotech company called Neostell SAS. Neovacs will own 70 percent of the new company and Stellar Biotechnologies will own the remaining 30 percent. Neovacs is a European leader in immunotherapies developed to treat autoimmune diseases. It’s lead active immunotherapy candidate is IFNα-Kinoid,…

Potential Lupus Immunotherapy Vaccine Advancing in France

Neovacs announced it has concluded a four-year, €5 million ($5.5 million) non-dilutive funding agreement to finalize clinical development and start the production process for its therapeutic IFN Kinoid vaccine. The funding, in the form of grants and repayable advances, came through a decision of The General Commission for Investment, operated by Bpifrance, a subsidiary of the French…

Potential Lupus Immunotherapy Gains a Marketing Partner for South Korea

Neovacs recently announced that it has signed an exclusive licensing contract granting Chong Kun Dang (CKD) Pharmaceutical Corp. of Seoul the right to market IFNα-Kinoïd, Neovacs’ anti-interferon alpha (IFNα) therapeutic vaccine being developed for the treatment of systemic lupus erythematosus (SLE), in South Korea. Lupus is considered an orphan disease in South…

Neovacs Ready to Launch IFN-K-002 Clinical Trial for Systemic Lupus Erythematosus After Receiving First Batch of EU Approvals

NEOVACS, a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases, announced it has been granted initial approvals by regulatory agencies and ethics committees in several countries in the European Union for a Phase IIb clinical study of investigational IFNα-Kinoid for patients…